New mRNA vaccine aims to shield older adults from RSV
NCT ID NCT07289542
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a new mRNA vaccine called ABO1105 against respiratory syncytial virus (RSV) in 420 healthy adults aged 50 and older. Participants receive either a low or high dose of the vaccine or a placebo. The study measures how well the vaccine boosts antibodies and checks for safety over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABO1105 (RSV mRNA vaccine)
- What this could lead to
- If successful, this could lead to a new vaccine option to protect older adults from respiratory syncytial virus (RSV).
- What could go wrong
- This is a mid-stage trial with only 420 participants, so results may not confirm effectiveness or safety in larger populations. The vaccine may not produce strong enough immunity or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baise Center For Disease Control & Prevention
Baise City, Baise, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine given during pregnancy shield infants from a deadly virus?
- Moderna's mRNA vaccine cocktail passes early safety check
- New RSV vaccine shows promise for seniors in korea
- Could a shot during pregnancy shield babies from RSV?
- RSV booster shot shows promise for seniors
- New mRNA RSV vaccine shows promise for older adults in phase 3 trial